The estimated Net Worth of Daniel Stanzione is at least $6.11 Million dollars as of 23 November 2020. Daniel Stanzione owns over 11,223 units of Quest Diagnostics stock worth over $4,353,272 and over the last 21 years he sold DGX stock worth over $1,417,465. In addition, he makes $340,544 as Lead Independent Director at Quest Diagnostics.
Daniel has made over 16 trades of the Quest Diagnostics stock since 2007, according to the Form 4 filled with the SEC. Most recently he sold 11,223 units of DGX stock worth $1,417,465 on 23 November 2020.
The largest trade he's ever made was buying 50,000 units of Quest Diagnostics stock on 14 September 2016 worth over $96,500. On average, Daniel trades about 6,152 units every 94 days since 2004. As of 23 November 2020 he still owns at least 28,349 units of Quest Diagnostics stock.
You can see the complete history of Daniel Stanzione stock trades at the bottom of the page.
Dr. Daniel C. Stanzione Ph.D. serves as Lead Independent Director of the Company. Dr. Stanzione retired from Lucent Technologies Incorporated in 2000 and is President Emeritus of Bell Laboratories and an independent consultant. Dr. Stanzione began his career in 1972 with Bell Laboratories, where he led the teams working on the first microprocessors and digital signal processors. He was appointed President of Network Systems, Lucent’s largest business unit, in 1996 and was appointed Chief Operating Officer of Lucent in 1997. Dr. Stanzione served as a director of Internap Corporation from 2005 to 2018 and served as a director of Avaya Inc. from 2000 until 2007. He has served on the boards of a number of private companies and currently is a director of Catheter Precision, Inc. Dr. Stanzione has been Lead Independent Director since January 1, 2017 and served as Chairman from May 1, 2012 until January 1, 2017.
As the Lead Independent Director of Quest Diagnostics, the total compensation of Daniel Stanzione at Quest Diagnostics is $340,544. There are 10 executives at Quest Diagnostics getting paid more, with Stephen Rusckowski having the highest compensation of $10,118,500.
Daniel Stanzione is 74, he's been the Lead Independent Director of Quest Diagnostics since 2017. There are 1 older and 20 younger executives at Quest Diagnostics. The oldest executive at Quest Diagnostics, Inc. is Gail Wilensky, 76, who is the Independent Director.
Over the last 21 years, insiders at Quest Diagnostics have traded over $67,426,608 worth of Quest Diagnostics stock and bought 34,000 units worth $1,910,090 . The most active insiders traders include Plc Gsk, James F Iii Flaherty und Jeffrey M Leiden. On average, Quest Diagnostics executives and independent directors trade stock every 19 days with the average trade being worth of $3,750,703. The most recent stock trade was executed by Michael E Prevoznik on 29 August 2024, trading 32,551 units of DGX stock currently worth $3,118,386.
quest diagnostics (nyse: dgx) empowers people to take action to improve health outcomes. derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. quest annually serves one in three adult americans and half the physicians and hospitals in the united states, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. the company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (ap) services, & interpretive consultation through its medical & scientific staff of about 900 m.d.s & ph.d.s. the company reported 2014 revenues of $7.4 billion. quest diagnostics offers the most extensive clinical testing network in the u.s., with laborator
Quest Diagnostics executives and other stock owners filed with the SEC include: